Bullish
Johnson & Johnson's stock reaches near 52-week high after Q2 earnings beat
Johnson & Johnson's stock has surged to near its 52-week high following a strong second-quarter earnings report. The company reported a 6.6% year-over-year increase in revenue, reaching $25.31 billion, and an adjusted earnings per share (EPS) of $2.90, surpassing analyst expectations. Additionally, the FDA approved IMAAVY, the first treatment for warm autoimmune hemolytic anemia, expanding J&J's presence in rare diseases.
Key points
- Q2 earnings report shows 6.6% revenue increase to $25.31 billion and adjusted EPS of $2.90, exceeding analyst expectations.
- FDA approves IMAAVY as first treatment for warm autoimmune hemolytic anemia, expanding J&J's rare disease portfolio.
- Bank of New York Mellon Corp sells 138,615 shares of J&J, reducing holdings by 0.6%.
- Johnson & Johnson's stock trades near 52-week high after Q2 earnings beat.
Sources
- Johnson & Johnson stock trades near 52-week high after Q2 beatAD HOC NEWS · August 26, 2026
- Johnson & Johnson (JNJ) Wins FDA Approval For First Warm Autoimmune Hemolytic Anemia TreatmentSimply Wall St News · August 26, 2026
- Bank of New York Mellon Corp Sells 138,615 Shares of Johnson & Johnson $JNJDefense World · August 28, 2026
- Johnson & Johnson stock trades near 52-week high after Q2 beatAD HOC NEWS · August 26, 2026
AI-generated from public news sources. Not financial advice.
